RLDC 2006 - Fourth
Annual
International
Pulmonary
Alveolar Proteinosis
Research Conference
Westin Hotel, Cincinnati, Ohio,
Friday, March 31 – Sunday, April 2, 2006
Scientific Conference Schedule
Friday Morning, March 31st,
7:30 am - 12:00
noon Westin - Taft I
Session I - RLDC Investigator's meeting:
Chair, Bruce
Trapnell, MD
7:30 - 8:00
Continental Breakfast
8:00 - 8:15
Bruce Trapnell, MD - "Welcome and RLDC Update"
8:15 - 9:00
Roundtable Discussions – RLDC Disease Groups
8:15 - 8:30
Bruce Trapnell, MD - "PAP Longitudinal, GM-CSF, Rituximab and other studies"
8:30 - 8:45
Frank McCormack, MD "Initiating the MILES Trial"
8:45 - 9:00
Charlie Strange, MD - "Longitudinal Study on Alpha-1 Antitrypsin Deficiency"
9:00 - 10:30
New Clinical Research Study Proposals
9:00 - 9:10 Bill
Hardie, MD "Proposal for a Phase I trial of Iressa for IPF"
9:10 - 9:30
Discussion: "Are we ready for a clinical trial of IRESSA in IPF"
9:30 - 9:40
Robert Vasallo, MD "Proposal for a LCH Longitudinal study"
9:40 - 10:00
Discussion - "Organizing an LCH Longitudinal study"
10:00 - 10:15 Robin
Deterding, MD - "Longitudinal study for NEHI"
10:15 - 10:30
Break
10:30 - 12:00
RLDC Investigator – Subject Enrollment Training Session
10:30 - 12:00
Jeffrey Krischer, PhD/DTCC Staff
12:00 - 1:00
Lunch
Westin - Presidential I
Friday Afternoon,
1:00 pm -
5:30 pm
Westin - Taft II
Session II -
PAP, Clinical Science:
Chair,
James Ellis, MD
1:00 - 1:05
Comments by Chair, James Ellis/Patient intro
1:05 - 1:15
Patient Speaker
1:15 - 1:35
Yoshikazu Inoue, MD, PhD - "Longitudinal Follow-Up Study of PAP Patients in
Japan"
1:35 - 1:55
Maurizio Luisetti, MD - "Longitudinal Follow-Up Study of
PAP Patients in Italy"
1:55 - 2:15
Haruyuki Ishii, MD - "Clinical Features of Anti-GM-CSF Antibody Negative PAP
Patients"
2:15 - 2:35 Mani
Kavuru, MD - "Evaluation of Subcutaneous GM-CSF Therapy for
PAP in USA"
2:35 -
2:55 Koh Nakata, MD, PhD - "Evaluation of Aerosolized GM-CSF Therapy for
PAP in Japan"
2:55 - 3:10
Break
Session
III -
PAP, Basic Science:
Chair, Toshihiro
Nukiwa, MD, PhD
Westin - Taft II
3:10 - 3:15
Comments by Chair, Toshihiro Nukiwa/Patient intro
3:15 - 3:25
Patient Speaker
3:25 - 3:40
Tracy Bonfield, PhD - Title to be determined
3:40 - 3:55
Hiroko Kanazawa, PhD - "Immunological abnormality in the blood of idiopathic
PAP"
3:55 - 4:10
Mary-Jane Thommason, PhD - Title to be determined
4:10 - 4:25
Haruko Iwabuchi, MD - "PAP-like alveolar macrophages in new-born rats"
4:25 - 4:40
Masato Watanabe, MD, PhD - "Anti-cytokine antibodies in PAP and healthy
individuals"
4:40 - 4:55
David Beck, MD - "Recapitulating PAP in non-human primates"
4:55 - 5:10
Kanji Uchida, MD, PhD - "Anti-GM-CSF antibodies in healthy individuals"
5:10 - 5:25
Abstract/To be determined
Friday Evening,
6:30 pm -
8:00 pm
Westin - Presidential Ballroom
RLDC Combined Investigator's & Patient's Dinner
6:00 - 7:00
Welcome Reception / Hors d'oeuvres
7:00 - 8:30
Dinner & Dessert
8:30 - 10:00 Free
time for discussion
Saturday Morning, April 1st,
7:30 pm - 12:00
noon Hilton - Pavilion
Session IV - RLDC Combined Science
Program:
Chair, Bruce Trapnell, MD
7:30 – 8:00
Continental Breakfast
8:00 – 8:05
Comments by Chair, Bruce Trapnell/Patient intro
8:05 – 8:15
Patient Speaker – Michele Manion, PCD Foundation
8:15 – 8:55 Marc
Achen, PhD: “Mechanisms of Lymphangiogenesis”
8:55 – 9:35
Koichi Hagiwara, MD, PhD: “Genetic Basis of Pulmonary Alveolar
Microlithiasis”
9:35 – 10:15
Robert Vassallo, MD: “Advances in Langerhan’s Cell Histiocytosis”
10:15 – 10:40
Break
10:40 – 11:20
Maimoona Zariwala, PhD: “A novel Genetic Test for Patients with Primary
Ciliary Dyskinesia”
11:20 – 12:00
Toshihiro Nukiwa, MD, PhD: “Acute Exacerbation in IPF patients; Rare in US,
Common in Japan"
12:00 – 2:00
Poster Session and Boxed Lunch
Pavillon/Caprice–Level IV
Saturday Afternoon,
1:00 pm -
5:30 pm
Westin - Taft II
Session V - Workshop, Developing
New/Better Therapies for
PAP:
Chair, Mani Kavuru, MD
2:00 - 2:05
Comments by Chair, Mani Kavuru/Patient intro
2:05 - 2:15
Patient Speaker
2:15 - 2:35
Bruce Trapnell, MD, "Proposed PAP Longitudinal Study Design"
2:35 - 4:10
Round Table Discussion - no formal presentations
2:35 - 2:55 "How
and when should whole lung lavage be used in the treatment of
PAP?"
2:55 - 3:15 "How
and when should GM-CSF be used in the treatment of
PAP?"
3:15 - 3:35 "How
and when should plasmapheresis be used in the treatment of
PAP?"
3:35 - 3:55
"Progress towards clinical evaluation of Rituximab as a treatment for PAP"
3:55 - 4:10
Break
Session VI - Workshop, Harmonizing Clinical Assessment of
PAP:
Chair, Cliff Morgan, MD
Westin - Taft II
4:10 - 5:30
Round Table Discussion - no formal presentations
4:10 - 4:25
How should the diagnosis of primary (idiopathic)
PAP be made in 2006?
4:25 - 4:40 How
should the severity of lung disease in primary PAP be judged?
4:40 - 4:55 What
are the indications for therapy for primary PAP, and Is there consensus?
4:55 - 5:10 What
is the best nomenclature for the various forms of
PAP?
5:10 - 5:25
Standardizing Anti-GM-CSF Antibody Titer Methods"
Saturday Evening,
6:30 pm -
9:00 pm
Westin
- Hayes
PAP Foundation Dinner & Board Meeting:
Chairs, Louie Schimpf & Bruce Trapnell, MD
6:30 - 7:30
Dinner
7:30 - 9:00 PAP
Foundation Board Meeting
9:00 - 9:30
Questions from the PAP community
Sunday Morning, April 2nd, 7:30
am - 12:00 Noon Westin - Taft I
Session
VII – Round Table Discussion,
PAP Clinical Research Studies:
Chair, Koh
Nakata, MD, PhD
7:30 - 8:00
Continental Breakfast
8:00 - 10:00 Jon
Puchalski, MD/RLDC PAP Study Group – “Finalizing the RLDC PAP Longitudinal
Study”
10:00 - 10:15
Break
10:15 - 12:00 Koh
Nakata, MD, PhD - "Manuscript Preparation: Cross-Sectional Study of PAP in
Japan"
| 
